Retatrutide vs Mazdutide: Comparing Next-Generation Incretin Agonists in Preclinical Research

The incretin field has moved past single-target GLP-1 pharmacology into a generation of multi-receptor agonists that co-engage GLP-1, GIP, and glucagon in different combinations. Some compounds hit all three receptors at once, others pair two pathways with a deliberate emphasis on one organ system, and the differences between these designs are not cosmetic. They shape which endpoints move first in preclinical models, which populations show the largest effect sizes in trials, and which mechanistic questions each compound is actually built to answer.

Retatrutide vs Mazdutide is the cleanest illustration of that split currently available in the pipeline. Retatrutide activates GLP-1, GIP, and glucagon receptors, with a potency profile now understood to be GIP-biased rather than truly equipotent. Mazdutide is a dual GLP-1/glucagon receptor agonist with no GIP activity, engineered around a hepatic center of gravity. Both compounds have advanced into late-stage clinical territory over roughly the same window, which makes them structurally comparable at the pipeline level even though their receptor logic is very different.

For research groups working through the weight loss & metabolic peptides group, understanding how the two designs behave differently at the receptor level is the entry point to selecting the right tool for a given hypothesis. This is also one of the earliest triple GLP-1 agonist comparison questions with meaningful preclinical and Phase 2/3 data on both sides.

Retatrutide: Receptor Balance and Clinical Pipeline

Retatrutide emerged from Eli Lilly’s incretin pipeline as a single peptide that engages all three incretin-family receptors. Structural pharmacology work indicates its potency is not equipotent across the three targets. GIP receptor activation is strongest, GLP-1 sits in the middle, and glucagon receptor engagement is the weakest of the three. This is vital when framing the compound: retatrutide is a broadly acting triple agonist, but it is GIP-biased, not symmetric.

Receptor Profile and Binding Characteristics

Retatrutide shows high affinity at all three receptors in the picomolar range, with the potency ranking above driving how downstream signaling actually plays out. In preclinical models, the effect distributes across appetite regulation (via GLP-1), glucose-dependent insulin secretion (via GIP), and hepatic and adipose metabolism (via glucagon receptor signaling). Because glucagon is the least potent of the three engagements, hepatic-only endpoints tend to move less dramatically with retatrutide than with a compound engineered around a glucagon-dominant profile.

Preclinical Evidence

Rodent studies of retatrutide report dose-dependent reductions in fat mass with relative preservation of lean tissue, improved glucose tolerance in both fasted and challenge states, and improvements in hepatic steatosis markers in diet-induced obesity models. In many preclinical models, hepatic endpoint gains sit below what glucagon-dominant designs produce at matched systemic effect, which is exactly what the receptor-potency ranking predicts.

Clinical Development Status

The NEJM Phase 2 trial reported approximately 24% mean weight loss at the top dose over 48 weeks, dose-dependent HbA1c reductions, and improvements in lipids and liver enzymes, with a safety profile dominated by GI events typical of the incretin class. [1]

In Phase 3, Lilly has reported topline results for TRIUMPH-1 (obesity), with all doses (4 mg, 9 mg, 12 mg) meeting primary and key secondary endpoints at 80 weeks and the 12 mg arm at roughly 28.3% mean weight loss, and for TRANSCEND-T2D-1 (type 2 diabetes), showing superior A1C reduction and weight loss versus placebo at 40 weeks with MRI-PDFF improvements in hepatic fat. [2][3]

Mazdutide: Glucagon-Dominant Design and NASH Applications

Mazdutide (IBI362, LY3305677) is a very different molecule. It is a dual GLP-1/glucagon receptor co-agonist developed by Innovent Biologics in partnership with Eli Lilly. It has no GIP activity by design. China’s NMPA approved it in February 2025 for chronic weight management, marketed as Mazdubio; it completed the GLORY-1 obesity Phase 3 in Chinese adults with overweight or obesity, and has an NDA for a T2D indication under review.

Receptor Profile and Design Rationale

The dual-agonist architecture reflects a deliberate bet: keep GLP-1-mediated appetite suppression, increase glucagon receptor activation to drive hepatic energy expenditure and lipid handling, and drop GIP entirely. Removing GIP simplifies interpreting any observed change in glucose homeostasis, since insulinotropic drive is now routed only through GLP-1.

Glucagon receptor activation in this context is not the “raises blood glucose” cartoon of endogenous glucagon. Chronic pharmacologic glucagon co-agonism, delivered against a background of strong GLP-1 signaling, increases hepatic fatty acid oxidation, suppresses lipogenic transcription factors, and reduces hepatic triglyceride content. That is the mechanistic pitch behind Mazdutide NASH research and the reason Mazdutide reads as a liver-first compound.

The dual GLP-1/glucagon strategy has deep preclinical roots. Rodent studies from 2009 established that GLP-1/glucagon co-agonism reverses diet-induced obesity in mice (2009 rodent co-agonist studies), and that early work provides the theoretical foundation for mazdutide’s design nearly two decades later.

Preclinical Evidence in Liver-Focused Models

In rodent models of diet-induced fatty liver, mazdutide substantially reduces hepatic triglyceride content, with histological improvements in hepatocyte ballooning and inflammatory infiltrate. Recent mechanistic reviews describe amelioration of metabolic dysfunction-associated steatotic liver disease through endoplasmic reticulum stress modulation and shifts in lipid metabolism. [5] Circulating triglycerides fall in a pattern consistent with reduced hepatic VLDL output. Body weight reductions in preclinical work are meaningful but tend to trail true triple-agonist compounds at matched dose, which again is what the receptor design predicts.

Research Applications and Positioning

For research programs where the endpoint is hepatic steatosis, hepatocellular inflammation, fibrosis staging, or hepatocyte-autonomous lipid handling, the mazdutide design offers a cleaner experimental signal than a triple agonist would. There is one less receptor pathway to control for, and the glucagon component is doing more of the mechanistic work.

Mechanistic Differences: Receptor Affinity Ratios Compared

GLP-1 Receptor Engagement

Both compounds bind GLP-1 with high affinity, and both drive GLP-1-mediated appetite suppression and glucose-dependent insulin secretion. Meaningful pharmacological differentiation at this receptor alone is modest.

GIP Receptor Engagement

This is where the two compounds diverge structurally. Retatrutide carries a GIP arm, and in retatrutide’s case that arm is the strongest of the three by potency. Mazdutide has no GIP activity. For any endpoint sensitive to GIP signaling — adipose insulin sensitivity, secondary insulinotropic drive, or GIP-dependent CNS effects — the two compounds are simply not comparable.

Glucagon Receptor Engagement

Both activate glucagon receptors, but the architectural weight is very different. In retatrutide, glucagon is the weakest of three parallel engagements. In mazdutide, glucagon is one of two pathways and functionally the dominant hepatic driver. This is why mazdutide reads as a hepatic tool, and retatrutide reads as a systemic one, even though both technically engage the glucagon receptor.

Hepatic vs. Systemic Metabolic Endpoints

Hepatic-Focused Research

For MASLD, NASH, fibrosis, or hepatocyte lipid biology, mazdutide’s dual architecture is the more disciplined instrument. There is no GIP-mediated modulation of insulin secretion competing with the glucagon-driven hepatic phenotype, which makes it easier to attribute observed changes to the mechanism under study.

Systemic Metabolic Research

For obesity models where the interesting biology is cross-tissue coordination, retatrutide is the more physiologically representative tool. The GIP component adds a glucose-responsive insulin secretion pathway that operates in parallel with GLP-1 and glucagon signaling, so the compound produces a broader set of metabolic effects across the pancreas, adipose tissue, muscle, and liver.

Dual-Endpoint Programs

A NASH histology program logically points to mazdutide. A program tracking integrated appetite, glucose disposal, and energy expenditure across multiple tissues logically points to retatrutide. These are not competing compounds. They answer different questions.

Current Preclinical and Clinical Research Data

Retatrutide’s Evidence Base

Retatrutide has the peer-reviewed Phase 2 obesity signal from Jastreboff and colleagues in NEJM as its foundational human dataset. [1] Lilly has reported Phase 3 topline results from TRIUMPH-1 and TRANSCEND-T2D-1, with peer-reviewed publications still emerging [2][3]; both trials are indexed in the public ClinicalTrials.gov registry (NCT05929066 for TRIUMPH-1, NCT06354660 for TRANSCEND-T2D-1). Hepatic PDFF improvements were included in reported outcomes. Safety data continue to align with the incretin class GI profile, with glucagon-related monitoring ongoing.

Mazdutide’s Data Profile

Mazdutide’s peer-reviewed pivotal data come from GLORY-1, the Phase 3 obesity trial in Chinese adults with overweight or obesity, published in NEJM. Mean weight loss in that trial was roughly 11–15% at 48 weeks, with improvements in metabolic and hepatic markers. [4] GLORY-2 has since reported higher weight-loss magnitudes at the 9 mg dose, roughly 16–19% at 60 weeks. [7] Foundational human safety and dose-escalation data come from the Bhattachar Phase 1 high-dose trial published in Diabetes, Obesity and Metabolism, which reached 16 mg and showed dose-dependent weight and metabolic changes. That study is a Phase 1 dose-escalation trial, not a comparative review of retatrutide and mazdutide. [6]

Comparative Evidence

Direct head-to-head data between the two compounds do not yet exist in the public literature, and any current comparison is indirect. In our reading, the indirect signal is consistent with the mechanistic prediction: mazdutide reduces hepatic steatosis and inflammation markers efficiently at matched systemic effect in liver-focused models, while retatrutide currently posts the larger absolute weight-loss numbers at high dose (Phase 2 ~24% at 48 weeks and TRIUMPH-1 ~28.3% at 80 weeks, versus GLORY-1 ~11–15% at 48 weeks and GLORY-2 9 mg ~16–19% at 60 weeks). That gap could narrow as higher mazdutide doses and longer follow-up mature, and as retatrutide’s Phase 3 hepatic endpoints appear in full peer-reviewed form.

Research Design Considerations for Each Compound

When Mazdutide Fits Your Study

Mazdutide is the better instrument if the primary endpoints are hepatic. That includes NASH histology, hepatocellular inflammation scoring, fibrosis staging, hepatocyte triglyceride content, mitochondrial function in the liver, and dissecting how glucagon signaling interacts with GLP-1 in liver tissue without a GIP confound. It is also the more appropriate choice for programs specifically interrogating GLP-1/glucagon receptor pharmacology as a category.

When Retatrutide Fits Your Study

Retatrutide is the better tool for integrated whole-body metabolic questions: cross-tissue coordination between appetite, glucose homeostasis, and energy expenditure; metabolic syndrome models where balanced systemic correction is the point; and studies that need a GLP-1/GIP/glucagon triple agonist for its GIP arm. It also carries the larger current human dataset, which matters for research that will eventually be positioned against clinical translation.

Differentiation Within the Triple Agonist Class

Triple-agonist and dual-agonist designs are competing hypotheses about what optimal metabolic pharmacology looks like. Retatrutide represents the bet that concurrent activation of GLP-1, GIP, and glucagon, even with a GIP-biased potency ranking, produces the most complete metabolic correction. Mazdutide represents the bet that dropping GIP and leaning into hepatic glucagon co-agonism produces a cleaner liver phenotype and a more mechanistically targeted tool for MASLD/NASH biology.

Neither hypothesis has been decisively resolved yet, which is part of what makes this comparison interesting at the current pipeline stage. As the peer-reviewed Phase 3 record fills in on both sides and as indirect comparisons across trials sharpen, the field will get a clearer sense of where each design actually earns its keep.

Research groups working through related mechanistic questions may also find comparisons like tirzepatide vs retatrutide useful, since the tirzepatide contrast isolates the effect of adding a glucagon arm on top of a GLP-1/GIP backbone.

The content on this page is for informational and educational purposes only and is not intended as medical advice. Med Supply Solutions does not sell or distribute research peptides. All research must be conducted by qualified professionals in accordance with applicable laws and regulations.

Citations

[1] Jastreboff, Ania M et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.” The New England journal of medicine vol. 389,6 (2023): 514-526. doi:10.1056/NEJMoa2301972

[2] Eli Lilly and Company. “Lilly’s Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes.” Eli Lilly and Company, 19 Mar. 2026, investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant.

[3] Eli Lilly and Company. “A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1).” ClinicalTrials.gov, National Library of Medicine, NCT05929066, clinicaltrials.gov/study/NCT05929066; and “Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1).” ClinicalTrials.gov, National Library of Medicine, NCT06354660, clinicaltrials.gov/study/NCT06354660.

[4] Ji, Linong et al. “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.” The New England journal of medicine vol. 392,22 (2025): 2215-2225. doi:10.1056/NEJMoa2411528

[5] Deng, Chen-Xi, et al. “Mazdutide: An Emerging Glucagon/GCG-Like Peptide-1 Dual Receptor Agonist for Obesity—A Comparison of Therapeutic Effects and Potential Side Effects with GCG-Like Peptide-1 Inhibitors. doi:https://doi.org/10.5497/wjp.v15.i1.113080.

[6] Bhattachar, Shobha N et al. “Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.” Diabetes, obesity & metabolism vol. 27,11 (2025): 6460-6469. doi:10.1111/dom.70040

[7] Innovent Biologics, Inc. “The Phase 3 GLORY-2 Study of Mazdutide 9 mg in Chinese Adults with Moderate to Severe Obesity Was Simultaneously Published in JAMA and Presented at the ADA Scientific Sessions.” Innovent Biologics, 8 June 2026, en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=603.